Navigation Links
MagPrep® Streptavidin Beads

ProductsMagPrep® Streptavidin Beads
Company EMD Biosciences, Inc.
Item MagPrep® Streptavidin Beads
Features 
  • The coating and dense layer of streptavidin on the surface guarantee binding capacity.
  • The size of the beads ensures that they remain suspended in solution during the binding process and the magnetite content (40%) allows separation from the aqueous phase using a magnet.
  • MagPrep Streptavidin Beads are for molecular applications such as hybrid capture techniques, e.g., isolation and enrichment of specific DNA sequences or mRNAs using appropriate biotinylated probes or primers.
  • The beads are compatible with downstream applications such as sequencing and cDNA synthesis, and can also be used for isolation of biotinylated antibodies or other biotinylated targets.
Description MagPrep® Streptavidin Beads are encapsulated super-paramagnetic polystyrol particles coated with streptavidin. The beads have a diameter of 1 m and are provided as a stabilized aqueous suspension of 10 mg / ml.
Info EMD Biosciences, Inc.
Customer Service: 800 854 3417
Web site: http://www.emdbiosciences.com/home.asp

Related medicine products :

1. Streptavidin Magnetic Beads
2. Dynabeads® MyOne™ Streptavidin T1
3. QuantumPlex Streptavidin Beads
4. Streptavidin MicroBeads
5. MagnaBind™ Streptavidin Beads
6. BcMag Streptavidin Magnetic Beads
7. Streptavidin A-Beads
8. Biotin-Trapper™ Streptavidin Magnetic Beads
9. Streptavidin functionalized M-PVA Magnetic Beads
10. Hi-Flux™ Streptavidin Magnetic Beads
11. MagaCell™-Streptavidin
The 570-90 is capable of producing up to 500 volts or 2,500 milliamps. It is an excellent choice for running all types of electroblotting applications. Also ideal for PAGE, SDS-PAGE, and DNA or RNA s...
... for horizontal and vertical gel electrophoresis applications. ... In this power supply model, output is ... constant voltage. Four sets of output terminals ... This power supply's light, compact and stackable ...
... The e-power series power ... any horizontal gel electrophoresis system. ... constructed to the most rigorous ... recognition as the most compact ...
... The PowerEase® 500 Power ... mini-gel electrophoresis. It offers extensive ... and four custom methods for ... own preferences. The simple, intuitive ...
Medicine Products:
(Date:11/26/2014)... (PRWEB) November 26, 2014 The ... Cardiology have launched a partnership designed to improve ... for congestive heart failure (CHF) patients in the ... staff and Lourdes Cardiology team will help CHF ... supervised protocols. This partnership pairs the Cardiac Recovery ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Increasing ... stringent drug safety regulations are expected to be ... period. Growing prevalence of acute and chronic ailments ... for new drug development. Moreover, growing adverse drug ... the same has become the need of the ...
(Date:11/26/2014)... Raleigh, NC (PRWEB) November 26, 2014 ... types of materials science can cause mesothelioma that looks ... just posted a new article on the research. ... at the Fraunhofer Institute for Toxicology and Experimental Medicine ... nanotubes. While all of the rats eventually ...
(Date:11/26/2014)... The city of San Diego, California, because ... with a plan to recycle wastewater – also called ... supports the San Diego plan as part of her ... Kleyne, by recycling water that San Diego already owns, ... greatly reduced. (Spagat, E, “San Diego looks to sewers ...
(Date:11/26/2014)... 26, 2014 Loffler Companies has been ... in Imaging, an online information and news publication for ... the sixth consecutive year Loffler has earned this prestigious ... The Elite Dealer Awards honor the best and the ... Elite Dealer honorees were chosen for their innovative marketing ...
Breaking Medicine News(10 mins):Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 2Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 3Health News:Pharmacovigilance Market To 2020 - Global Industry Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 2Health News:Pharmacovigilance Market To 2020 - Global Industry Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Global fresh water advocate supports San Diego wastewater recycling plan 2Health News:Global fresh water advocate supports San Diego wastewater recycling plan 3Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2
... By Amanda Gardner HealthDay Reporter , ... announced Thursday that they will lower the maximum amount ... products such as Vicodin and Percocet because of reports ... three years, the upper threshold of acetaminophen in prescription ...
... high blood pressure, according to new research by the University ... pressure or hypertension is one of the major ... and costs more than $300 billion each year. Around a ... 10 million people in the UK and one in three ...
... News) -- The more you walk, the lower your risk ... middle-aged adults who participated in a study to map diabetes ... health examination at the start of the study and provided ... were also given a pedometer and instructed how to use ...
... Randy Dotinga HealthDay Reporter , THURSDAY, Jan. ... severely obese women who suffer from incontinence, a new ... after undergoing gastric-band weight-loss surgery. "This could ... said Dr. Weranja K.B. Ranasinghe, the study,s lead author. ...
... Massachusetts General Hospital (MGH) Cancer Center researchers have discovered a ... of certain DNA sequences that do not code for proteins. ... been studied for their role in chromosomal structure but previously ... The report will appear in the journal Science ...
... News) -- Differences in income, gender and race influence ... a federal government report released Thursday shows. While ... healthy lives, disparities persist, according to the U.S. Centers ... people have five to 11 times fewer healthy days ...
Cached Medicine News:Health News:FDA Lowers Amount of Acetaminophen Allowed in Prescription Painkillers 2Health News:FDA Lowers Amount of Acetaminophen Allowed in Prescription Painkillers 3Health News:Bioactive compounds in berries can reduce high blood pressure 2Health News:The More You Walk, the Lower Your Diabetes Risk: Study 2Health News:Weight-Loss Surgery May Ease Incontinence in Women 2Health News:Weight-Loss Surgery May Ease Incontinence in Women 3Health News:Overexpression of repetitive DNA sequences discovered in common tumor cells 2Health News:Health Disparities Persist in U.S., Report Shows 2
(Date:11/26/2014)... , November 25, 2014 ... Instruments Market by Power Source (Electric, Battery, Pneumatic), ... Cables, Blade, Burr, Cart), by Application (Orthopedic, ENT, ... published by MarketsandMarkets, the global Powered Surgical Instruments Market ... $1.6 Billion in 2014 and is expected to ...
(Date:11/26/2014)... Calif. , Nov. 25, 2014 /PRNewswire/ ... company focused on the development of mobile ... accurate testing in hospital and pre-hospital settings, ... Organization (ISO) 13485:2003 certification.  The certification was ... one of the world,s leading certification bodies. ...
(Date:11/26/2014)... OAKS, Calif. and LONDON , ... ) and AstraZeneca (NYSE: AZN ) today announced ... evaluating two doses of brodalumab in more than 1,800 patients ... with both Stelara ® (ustekinumab) and placebo at week ... brodalumab weight-based analysis group were each shown to be superior ...
Breaking Medicine Technology:Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Nanomix Receives ISO 13485:2003 Certification 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10